Improving Product Quality and Productivity of Bispecific Molecules Through the Application of Continuous Perfusion Principles.
Sign Up to like & getrecommendations! Published in 2020 at "Biotechnology progress"
DOI: 10.1002/btpr.2973
Abstract: Bispecific protein scaffolds can be more complex than traditional monoclonal antibodies (MAbs) because two different sites/domains for epitope binding are needed. Because of this increased molecular complexity, bispecific molecules are difficult to express and can… read more here.
Keywords: perfusion; product; process; product quality ... See more keywords
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase 1 Clinical Trials.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2929
Abstract: Rozibafusp alfa (AMG 570) is a first-in-class bispecific IgG2-peptide fusion designed to inhibit inducible T-cell costimulator ligand (ICOSL) and B-cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in… read more here.
Keywords: baff; rozibafusp alfa; bispecific; icosl ... See more keywords
Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats
Sign Up to like & getrecommendations! Published in 2020 at "Current Medical Science"
DOI: 10.1007/s11596-020-2143-y
Abstract: Selecting an ideal molecular format from diverse structures is a major challenge in developing a bispecific antibody (BsAb). To choose an ideal format of anti-CD3 × anti-transferrin receptor (TfR) bispecific antibodies for clinical application, we… read more here.
Keywords: chain; bispecific cell; anti transferrin; cell engager ... See more keywords
A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies.
Sign Up to like & getrecommendations! Published in 2020 at "Protein expression and purification"
DOI: 10.1016/j.pep.2020.105647
Abstract: WuXiBody is a novel bispecific antibody (bsAb) platform developed by WuXi Biologics. It enables almost any monoclonal antibody (mAb) sequence pair to be assembled into a bispecific construct. BsAbs based on WuXiBody can adopt either… read more here.
Keywords: platform approach; approach wuxibody; platform; wuxibody based ... See more keywords
Bispecific antibodies for the treatment of haemophilia A.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2021.1940133
Abstract: INTRODUCTION : Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as… read more here.
Keywords: treatment; antibodies treatment; treatment haemophilia; bispecific antibodies ... See more keywords
Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries
Sign Up to like & getrecommendations! Published in 2021 at "mAbs"
DOI: 10.1080/19420862.2020.1859049
Abstract: ABSTRACT Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging. Here we describe a high-throughput, combinatorial, phenotypic screening approach using a new bispecific antibody target discovery format,… read more here.
Keywords: target; bispecific; discovery; cell ... See more keywords
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
Sign Up to like & getrecommendations! Published in 2020 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aaw7888
Abstract: CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy. Double trouble for tumors Bispecific antibodies, which have one arm that binds to a cancer… read more here.
Keywords: cd3; cd28; costimulatory; bispecific antibodies ... See more keywords
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abn1082
Abstract: Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a complete response to frontline chemoimmunotherapy, patients with relapsed/refractory disease typically have poor outcomes. Odronextamab, a CD20xCD3 bispecific antibody that provides “signal 1”… read more here.
Keywords: cell; lymphoma; bispecific antibody; bispecific ... See more keywords
Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Immunology Research"
DOI: 10.1155/2019/4516041
Abstract: Bispecific antibodies (BsAbs) are a sort of dual functional proteins with specific binding to two distinct targets, which have become a focus of interest in antibody engineering and drug development research and have a promising… read more here.
Keywords: immunoglobulin gamma; igg like; antibody; tumor therapy ... See more keywords
Abstract 3631: Delivery of a CD20 transferrin receptor VNAR bispecific antibody to the brain for CNS lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3631
Abstract: Penetration of the blood brain barrier (BBB) remains a significant hurdle in the development of biologic therapeutics for CNS-related cancers. Antibody-based molecules typically do not cross the BBB in amounts required for therapeutic efficacy. Receptor-mediated… read more here.
Keywords: tfr1; delivery; receptor; cd20 ... See more keywords
Abstract 3638: AMX-168, a long-acting, tumor protease-sensitive bispecific precursor for the treatment of solid malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3638
Abstract: Bispecific T cell engagers (BiTE®) recruit highly cytotoxic host CD3+ T cells for destruction of tumor antigen-specific malignant cells. Bearing a defined single-chain antibody fragment (scFv) binding to CD3 on T cells and a selected… read more here.
Keywords: protease; amx 168; long acting; bispecific ... See more keywords